Trial · NCT01154452
Adverse events228
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
1 to 20 of 228
Download this page as JSON| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Activated partial thromboplastin time prolonged | Investigations | RO4929097 10mg | 1 | 6 | 1 |
| other | Activated partial thromboplastin time prolonged | Investigations | RO4929097 15 mg | 1 | 4 | 2 |
| other | Activated partial thromboplastin time prolonged | Investigations | ARM 1 - RO4929097: 15 mg PO QD | 0 | 35 | 0 |
| other | Activated partial thromboplastin time prolonged | Investigations | ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD | 0 | 33 | 0 |
| other | Anemia | Blood and lymphatic system disorders | RO4929097 10mg | 1 | 6 | 12 |
| other | Anemia | Blood and lymphatic system disorders | RO4929097 15 mg | 3 | 4 | 42 |
| other | Anemia | Blood and lymphatic system disorders | ARM 1 - RO4929097: 15 mg PO QD | 11 | 35 | 56 |
| other | Anemia | Blood and lymphatic system disorders | ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD | 8 | 33 | 32 |
| other | Blurred vision | Eye disorders | RO4929097 10mg | 1 | 6 | 1 |
| other | Blurred vision | Eye disorders | RO4929097 15 mg | 0 | 4 | 0 |
| other | Blurred vision | Eye disorders | ARM 1 - RO4929097: 15 mg PO QD | 0 | 35 | 0 |
| other | Blurred vision | Eye disorders | ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD | 0 | 33 | 0 |
| other | Hypercalcemia | Metabolism and nutrition disorders | RO4929097 10mg | 1 | 6 | 1 |
| other | Hypercalcemia | Metabolism and nutrition disorders | RO4929097 15 mg | 0 | 4 | 0 |
| other | Hypercalcemia | Metabolism and nutrition disorders | ARM 1 - RO4929097: 15 mg PO QD | 0 | 35 | 0 |
| other | Hypercalcemia | Metabolism and nutrition disorders | ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD | 0 | 33 | 0 |
| other | Hyperglycemia | Metabolism and nutrition disorders | RO4929097 10mg | 1 | 6 | 1 |
| other | Hyperglycemia | Metabolism and nutrition disorders | RO4929097 15 mg | 2 | 4 | 4 |
| other | Hyperglycemia | Metabolism and nutrition disorders | ARM 1 - RO4929097: 15 mg PO QD | 6 | 35 | 34 |
| other | Hyperglycemia | Metabolism and nutrition disorders | ARM 2: GDC-0449 150 mg PO QD and RO4929097 15 mg PO QD | 5 | 33 | 10 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01154452/events